TBX22 Inhibitors
Chemical inhibitors of TBX22 can interfere with the protein's function by targeting various signaling pathways that are crucial for its activity. SB-431542, LY364947, A-83-01, RepSox, SB-505124, Galunisertib, and EW-7197, are molecules that inhibit the TGF-β signaling pathway at different points. SB-431542, A-83-01, and RepSox specifically inhibit ALK5, ALK4, and ALK7 receptors, which are integral to the TGF-β pathway that TBX22 utilizes. LY364947 and Galunisertib, on the other hand, target TGFβR-I, a receptor whose activity is necessary for TBX22's role in cellular processes. SB-505124 also falls into this category, selectively inhibiting ALK4, ALK5, and ALK7 receptors within the same pathway. EW-7197 further contributes to the inhibition of TBX22 by selectively targeting the TGF-β type I receptor ALK5 kinase. By inhibiting these receptors or kinases, these chemicals disrupt the signaling cascade, preventing TBX22 from carrying out its function within the pathway.
Conversely, Dorsomorphin, LDN-193189, DMH1, LDN-214117, and K02288 act upon the bone morphogenetic protein (BMP) signaling pathway, which is another route through which TBX22 can mediate its effects. Dorsomorphin and DMH1 are inhibitors that suppress BMP signaling, which is essential for the TBX22's involvement in craniofacial development. LDN-193189 and LDN-214117 are more selective, targeting BMP type I receptors that participate in TBX22's action in development. K02288 extends this inhibition by targeting a range of BMP type I receptors, including ALK1, ALK2, ALK3, and ALK6, all of which are necessary for the signaling that TBX22 requires. By blocking these critical receptors, these chemicals can effectively inhibit the functionality of TBX22, thereby inhibiting the signaling events TBX22 needs to exert its effects on cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is an inhibitor of the ALK5, ALK4, and ALK7 receptors, which are part of the TGF-β signaling pathway. TBX22 is known to interact with the TGF-β pathway, and inhibition of this pathway by SB-431542 can lead to the functional inhibition of TBX22 by preventing its activation or the downstream signaling required for its function. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 is a potent ATP-competitive inhibitor of the TGFβR-I receptor. By blocking TGFβR-I, LY364947 suppresses the TGF-β signaling pathway, which is necessary for the TBX22 function in the development and formation of specific structures, thereby inhibiting TBX22 function. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin inhibits BMP signaling, which TBX22 is involved in, particularly in craniofacial development and morphogenesis. By inhibiting BMP pathways, Dorsomorphin can lead to the functional inhibition of TBX22 by blocking the signaling events TBX22 needs to exert its effects on cellular processes. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 is a selective inhibitor of ALK5, ALK4, and ALK7, which are part of the TGF-β pathway that can interact with TBX22. Inhibition of these receptors by A-83-01 can functionally inhibit TBX22 by blocking the signaling pathways that TBX22 is involved in, thereby impairing its role. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox is an inhibitor of ALK5, which is part of the TGF-β signaling pathway. TBX22 interacts with this pathway, and inhibition by RepSox can prevent the necessary signaling for TBX22 to function, leading to its functional inhibition. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective BMP pathway inhibitor, which can indirectly inhibit TBX22 by blocking the BMP signaling that is necessary for TBX22’s role in development and cellular processes. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
SB-505124 selectively inhibits ALK4, ALK5, and ALK7, which are part of the TGF-β signaling pathway. The functional inhibition of TBX22 occurs as a result of the disruption of this pathway, which is required for TBX22 mediated activities. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP receptor inhibitor. By inhibiting BMP signaling, DMH1 can suppress the activity of TBX22, as it relies on BMP signaling for proper function in developmental processes. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 selectively inhibits BMP type I receptors ALK2/ACVR1, which are involved in signaling pathways that TBX22 participates in. By inhibiting these pathways, LDN-214117 leads to functional inhibition of TBX22. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
K02288 is a potent and selective inhibitor of the BMP type I receptors ALK1, ALK2, ALK3, and ALK6, which play a role in the signaling pathways that TBX22 is involved in. Inhibition of these receptors results in functional inhibition of TBX22 by impeding the signaling mechanisms it utilizes. | ||||||